Mounting evidence has indicated that maternal dyslipidemia is associated with adverse obstetric outcomes, and the actions of lipid-lowering drugs in pregnant women remain controversial. Hence, this study aimed to appraise the causal relationship of lipid-lowering drugs [hydroxymethylglutaryl-coenzyme reductase (HMGCR) inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors] with pregnancy and perinatal outcomes using drug-targeting Mendelian randomization analysis.

中文翻译：

---

降脂药物与妊娠和围产期结局之间的关联：孟德尔随机研究。

越来越多的证据表明，孕产妇血脂异常与不良产科结局相关，而降脂药物对孕妇的作用仍存在争议。因此，本研究旨在利用药物靶向孟德尔随机分析来评估降脂药物[羟甲基戊二酰辅酶还原酶（HMGCR）抑制剂、PCSK9抑制剂和NPC1L1抑制剂]与妊娠和围产期结局的因果关系。